Catalyst Capital Advisors LLC Purchases New Holdings in Insulet Co. (NASDAQ:PODD)

Catalyst Capital Advisors LLC purchased a new stake in shares of Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 7,400 shares of the medical instruments supplier’s stock, valued at approximately $1,267,000.

A number of other large investors have also recently modified their holdings of PODD. Meeder Asset Management Inc. bought a new position in Insulet during the 3rd quarter valued at about $293,000. Envestnet Asset Management Inc. grew its stake in Insulet by 11.4% in the 3rd quarter. Envestnet Asset Management Inc. now owns 24,408 shares of the medical instruments supplier’s stock worth $4,026,000 after acquiring an additional 2,507 shares in the last quarter. Wedbush Securities Inc. bought a new position in Insulet in the 3rd quarter worth about $207,000. First Citizens Bank & Trust Co. bought a new position in Insulet in the 3rd quarter worth about $695,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Insulet by 5.0% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,082 shares of the medical instruments supplier’s stock worth $673,000 after acquiring an additional 196 shares in the last quarter.

A number of equities analysts have commented on PODD shares. Cowen set a $165.00 target price on shares of Insulet and gave the stock a “buy” rating in a research note on Monday, October 21st. Stifel Nicolaus started coverage on shares of Insulet in a research note on Tuesday, October 22nd. They issued a “hold” rating and a $163.00 target price on the stock. JPMorgan Chase & Co. upped their target price on shares of Insulet from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 20th. Piper Jaffray Companies upped their target price on shares of Insulet from $170.00 to $200.00 and gave the stock an “overweight” rating in a research note on Monday, November 18th. Finally, Morgan Stanley upped their target price on shares of Insulet from $148.00 to $181.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and an average target price of $162.06.

In related news, Director John A. Fallon sold 14,525 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $181.21, for a total transaction of $2,632,075.25. Also, CEO Shacey Petrovic sold 12,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $169.63, for a total transaction of $2,120,375.00. Following the sale, the chief executive officer now directly owns 95,530 shares of the company’s stock, valued at approximately $16,204,753.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,909 shares of company stock worth $5,246,306. Insiders own 3.50% of the company’s stock.

NASDAQ PODD opened at $205.41 on Friday. The company has a debt-to-equity ratio of 6.55, a quick ratio of 6.21 and a current ratio of 7.01. The firm’s 50 day moving average price is $187.12 and its 200-day moving average price is $165.85. Insulet Co. has a 52-week low of $80.43 and a 52-week high of $207.28. The company has a market cap of $12.70 billion, a PE ratio of 790.07 and a beta of 0.77.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Further Reading: Understanding debt-to-equity ratio in fundamental analysis

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.